Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
HIVEP zinc finger 2 (HIVEP2) is a large human zinc finger transcription factor that binds directly to DNA, including enhancer elements of the major histocompatibility complex (MHC) and the human immunodeficiency virus type 1 (HIV-1) long terminal repeat (LTR). It contains multiple C2H2-type zinc finger domains and is known by several aliases, reflecting its roles in immune regulation and transcriptional control. HIVEP2 can downregulate the NF-κB pathway, a key transcriptional pathway for immune and inflammatory responses, and has been implicated in neural and developmental functions. Pathogenic variants in HIVEP2 cause a recognizable neurodevelopmental syndrome characterized by intellectual disability, developmental delay, and behavioral abnormalities. There are no approved drugs targeting HIVEP2 directly, and it is principally studied as a transcriptional regulator rather than a traditional drug target. Key information is deduced from UniProt, NCBI Gene, and relevant scientific literature. No specific drugs, mechanisms of action, or biomarker roles are described in current high-quality sources.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on HIVEP zinc finger 2 (HIVEP2).